Data on the safety and efficacy of biosimilar infliximab CT-P13 (Inflectra, Remsima) in treating inflammatory bowel disease (IBD) continue to accrue, in both adult patients and in pediatric patients, and a study from Finland adds to that body of knowledge, while another study in pediatric patients shows that Janus kinase (JAK) inhibitors may be an option for those who do not respond adequately to infliximab or other biologic treatment.
Data on the safety and efficacy of biosimilar infliximab CT-P13 (Inflectra, Remsima) in treating inflammatory bowel disease (IBD) continue to accrue, in both adult patients and in pediatric patients.
Recently, a study of patients treated for pediatric IBD at a single center in Finland added to that body of knowledge, finding that first-year therapy outcomes for patients treated with the biosimilar were comparable with those of patients treated with the reference drug.1
The investigators collected data on the outcomes of 51 patients who were naïve to anti—tumor necrosis factor therapy who started infliximab at a single center in Finland between 2015 and 2016. These patients had a median age of 12 years (range, 4-16 years) and 65% of them had Crohn disease (CD).
In total, 23 of the patients were treated with the reference infliximab, and the remaining 28 patients were given the biosimilar option; during 2015, the authors note, the reference infliximab was the option used for treatment-naïve patients, while during 2016, all new patients were given the biosimilar.
The researchers found no statistically significant differences between the 2 drugs in terms of therapy outcomes at 1 year, and there were no significant differences in tough levels between the 2 groups, nor were there notable differences in safety.
While that is reassuring news for health systems seeking to use cost-saving biosimilars in this patient population, some patients may not respond adequately to infliximab or other biologic treatment. In such cases, Janus kinase (JAK) inhibitors may be an option, and in other recent developments in the treatment of pediatric IBD, researchers from a different center reported on using tofacitinib in pediatric patients who did not have an adequate response to infliximab.2
The 12 patients treated with the JAK inhibitor tofacitinib included 5 patients with CD, 5 with ulcerative colitis (UC), and 2 with unclassified IBD, had all failed infliximab therapy, and 6 had failed 3 or more biologics before initiating treatment with the JAK inhibitor.
A clinical response during the observational period of 9.7 weeks (range, 8.3-12.0), measured using a weighted Pediatric Crohn's Disease Activity Index improvement of 17.5 points or more for CD and a decrease in the Pediatric Ulcerative Colitis Activity Index of 20 points or more for UC and unclassified IBD, was observed in 8 of the 12 patients. At the time of the last follow-up, 5 patients were in clinical remission, and 3 were in steroid-free clinical remission.
The researchers add that there have been no serious adverse events—including thromboembolic events—in this patient group.
“In our small pediatric cohort, tofacitinib appeared safe and provided a significant clinical benefit for a select group of refractory IBD patients,” write the authors.
References
1. Nikkonen A, Kolho K-L. Infliximab and its biosimilar produced similar first‐year therapy outcomes in patients with inflammatory bowel disease [published online September 19, 2019]. Acta Paediatr. doi: 10.1111/apa.15026.
2. Dollinger MT, Rolfes P, Phan BL, Dubinsky MC. Letter: tofacitinib use for biologic-refractory paediatric inflammatory bowel disease [published online October 7. 2019]. Aliment Pharmacol Ther. doi: 10.1111/apt.15496.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Phase 3 Trials Find Subcutaneous Infliximab CT-P13 Superior to Placebo in IBD
June 29th 2024Two phase 3 trials in patients with inflammatory bowel disease (IBD) found higher clinical remission rates in those treated with the subcutaneous formulation of infliximab biosimilar CT-P13 compared with placebo as maintenance therapy following an induction phase of intravenous CT-P13.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.